ClinicalTrials.gg
CompletedNCT06173531Updated Oct 15, 2026Results posted

Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

A Phase 3 interventional study of Carbetocin and Placebo in Hyperphagia in Prader-Willi Syndrome, sponsored by ACADIA Pharmaceuticals Inc.. Completed at 30 sites in 6 countries. Open to participants aged 5 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by ACADIA Pharmaceuticals Inc. · Phase 3, Interventional, and Treatment

How we know

Updated Oct 15, 2026Now CompletedResults posted+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
5 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Prader-Willi Syndrome with a site in United States — 9 open to participants now, 14 under way, 3 of them phase 3. Prader-Willi Syndrome · United States.

Enrollment
2nd of 58
175 · median 23
Started
2023
with 6 others
Phase 3
14 of 69
2 open now
Registered
58th of 69
by date
Lead sponsor
2 of 69
ACADIA Pharmaceuticals Inc.

Among the 69 studies in Prader-Willi Syndrome with a site in United States, this one is the 2nd largest by enrollment of the 58 interventional ones that give a count, is one of 7 that started in 2023, is one of 14 in phase 3, and was the 58th registered.

Prader-Willi Syndrome

144 studies on the registry are indexed under Prader-Willi Syndrome; 23 are open to participants now.

Browse Prader-Willi Syndrome studies →

Open to participants now

9 of the 69 studies in Prader-Willi Syndrome with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Prader-Willi Syndrome studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 5 Years to 30 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Prader-Willi Syndrome with a site in United States, or all of them as a file.
02

Study summary

12-week, randomized, double-blind, placebo-controlled, parallel-group study of carbetocin nasal spray for the treatment of hyperphagia in Prader-Willi syndrome (PWS)

Read the detailed description

This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study comparing carbetocin nasal spray 3.2 mg TID with placebo (matched placebo nasal spray TID) in subjects with PWS.

03

Conditions studied

  • Hyperphagia in Prader-Willi Syndrome

Browse trials for

Keywords

  • Randomized
  • Placebo-controlled
04

Who can participate

The criteria were revised on the registry on Oct 15, 2026. See what changed

Ages eligible
5 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants aged 5 to 30 years
  • Diagnosis of Prader-Willi syndrome with a documented disease-causing genetic mutation
  • Evidence of hyperphagia, including increased appetite and decreased satiety with food-seeking behaviors
  • Meeting minimum severity thresholds for hyperphagia based on validated clinical assessments at Screening and Baseline
  • Residing with a caregiver who is able and willing to comply with study procedures and participate in study visits

Exclusion criteria

Exclusion Criteria

  • Diagnosis of Schaaf-Yang syndrome or another genetic, hormonal, or chromosomal disorder other than Prader-Willi syndrome
  • Active upper respiratory infection at Screening or Baseline
  • medical conditions that could interfere with study participation or interpretation of results (e.g., cardiovascular, renal, hepatic, gastrointestinal, or respiratory disease)
  • History of significant neurological conditions (e.g., cerebrovascular disease, brain trauma, epilepsy, or frequent migraines), except for a history of febrile seizures
  • Recent or planned nasal surgery that could affect intranasal drug administration
  • Unwillingness to restrict use of intranasal medications that may interfere with study treatment
  • Recent clinically significant psychiatric instability, including irritability or agitation requiring changes in antipsychotic therapy
  • Use of medications or treatments that may interfere with the evaluation of hyperphagia or study endpoints within a defined period prior to Screening Active psychotic disorder or history of significant psychotic symptoms
  • History of suicide attempt or inpatient psychiatric hospitalization
  • Recent changes in food-related behavioral or environmental interventions that may confound assessment of hyperphagia

Additional inclusion and exclusion criteria apply. Participants will be evaluated at Screening to ensure all eligibility requirements are met.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
175 participants (actual)

Study arms

  • Experimental
    Carbetocin

    Carbetocin nasal spray 3.2 mg administered TID

    Drug: Carbetocin

  • Placebo comparator
    Placebo

    Matching placebo nasal spray administered TID

    Drug: Placebo

Interventions

  • Carbetocin nasal spray 3.2 mg administered TID

    Also known as: ACP-101

  • DrugPlacebo

    Matching placebo nasal spray administered TID

06

What researchers measure

Primary outcomes

  1. Change From Baseline at Week 12 in Hyperphagia Questionnaire for Clinical Trials (HQ-CT) Score

    The HQ-CT is a caregiver-reported, 9-item assessment of observable hyperphagia-related behaviors in participants with PWS. The questionnaire is administered to the caregiver by a trained rater using standardized prompts, and the same caregiver is expected to complete the assessment throughout the study whenever possible. Each item is scored from 0 to 4, resulting in a total score ranging from 0 to 36, with higher scores indicating greater severity of hyperphagia. A decrease from baseline reflects improvement, and a reduction of 7.7 points has been identified as a clinically meaningful within-participant improvement.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Change From Baseline at Week 12 in Clinical Global Impression of Severity (CGI-S) for PWS Score

    The CGI-S for PWS is a clinician-rated assessment of the overall severity of PWS symptoms at the time of evaluation. The CGI-S is rated on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most severely ill participants), with higher scores indicating greater illness severity. The assessment is performed by the Investigator or a trained, qualified designee, and the same rater is expected to evaluate a given participant throughout the study whenever possible to maintain rating consistency.

    Time frame: Baseline to Week 12

  2. Clinical Global Impression of Change (CGI-C) for PWS Score at Week 12

    The CGI-C for PWS is a clinician-rated assessment of change in the overall severity of PWS symptoms relative to Baseline. The CGI-C is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), with lower scores indicating greater improvement from Baseline. The assessment is performed by the Investigator or a trained, qualified designee, and the same rater is expected to evaluate a given participant throughout the study whenever possible to maintain rating consistency.

    Time frame: Week 12

  3. Percentage of Subjects With Treatment Response at Week 12 (Defined as Improvement From Baseline ≥8 Points) Based on the HQ-CT Score at Week 12

    Treatment response was defined as an improvement from Baseline of at least 8 points in the HQ-CT total score at Week 12. The HQ-CT is a caregiver-reported, 9-item assessment of observable hyperphagia-related behaviors in participants with PWS. Total scores range from 0 to 36, with higher scores indicating greater severity of hyperphagia. Participants meeting the ≥8-point improvement threshold were classified as responders.

    Time frame: Week 12

  4. Change From Baseline at Week 12 in CGI-S for Hyperphagia in PWS Score

    The CGI-S for PWS is a clinician-rated assessment of the overall severity of PWS symptoms at the time of evaluation. The CGI-S is rated on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most severely ill participants), with higher scores indicating greater illness severity. The assessment is performed by the Investigator or a trained, qualified designee, and the same rater is expected to evaluate a given participant throughout the study whenever possible to maintain rating consistency.

    Time frame: Baseline to Week 12

07

Results

Posted Oct 15, 2026

Participant flow

Participant flow — Overall Study
MilestoneCarbetocinPlacebo
Started8590
Completed8286
Not completed34

Outcome measures

PrimaryChange From Baseline at Week 12 in Hyperphagia Questionnaire for Clinical Trials (HQ-CT) Score

The HQ-CT is a caregiver-reported, 9-item assessment of observable hyperphagia-related behaviors in participants with PWS. The questionnaire is administered to the caregiver by a trained rater using standardized prompts, and the same caregiver is expected to complete the assessment throughout the study whenever possible. Each item is scored from 0 to 4, resulting in a total score ranging from 0 to 36, with higher scores indicating greater severity of hyperphagia. A decrease from baseline reflects improvement, and a reduction of 7.7 points has been identified as a clinically meaningful within-participant improvement.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · Score on a scale
Change From Baseline at Week 12 in Hyperphagia Questionnaire for Clinical Trials (HQ-CT) Score
Score on a scaleCarbetocinPlacebo
Change From Baseline at Week 12 in Hyperphagia Questionnaire for Clinical Trials (HQ-CT) Score-4.8 ± 0.78-5.1 ± 0.75
Statistical analysis
  • Carbetocin vs Placebo · Mixed-effects model for repeated measure · p = 0.7889 · Lsm difference: 0.3 · 95% CI -1.8 to 2.4Estimated using a mixed-effects model for repeated measures (MMRM) based on the Full Analysis Set; missing data handled under a missing at random assumption.
SecondaryChange From Baseline at Week 12 in Clinical Global Impression of Severity (CGI-S) for PWS Score

The CGI-S for PWS is a clinician-rated assessment of the overall severity of PWS symptoms at the time of evaluation. The CGI-S is rated on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most severely ill participants), with higher scores indicating greater illness severity. The assessment is performed by the Investigator or a trained, qualified designee, and the same rater is expected to evaluate a given participant throughout the study whenever possible to maintain rating consistency.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · Score on a scale
Change From Baseline at Week 12 in Clinical Global Impression of Severity (CGI-S) for PWS Score
Score on a scaleCarbetocinPlacebo
Change From Baseline at Week 12 in Clinical Global Impression of Severity (CGI-S) for PWS Score-0.4 ± 0.10-0.5 ± 0.10
Statistical analysis
  • Carbetocin vs Placebo · Mixed-effects model for repeated measure · p = 0.6507 · Lsm difference: 0.1 · 95% CI -0.2 to 0.3
SecondaryClinical Global Impression of Change (CGI-C) for PWS Score at Week 12

The CGI-C for PWS is a clinician-rated assessment of change in the overall severity of PWS symptoms relative to Baseline. The CGI-C is rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), with lower scores indicating greater improvement from Baseline. The assessment is performed by the Investigator or a trained, qualified designee, and the same rater is expected to evaluate a given participant throughout the study whenever possible to maintain rating consistency.

Time frame:
Week 12
Reported as:
Least squares mean · Score on a scale
Clinical Global Impression of Change (CGI-C) for PWS Score at Week 12
Score on a scaleCarbetocinPlacebo
Clinical Global Impression of Change (CGI-C) for PWS Score at Week 123.6 ± 0.123.6 ± 0.12
Statistical analysis
  • Carbetocin vs Placebo · Mixed-effects model for repeated measure · p = 0.9272 · Lsm difference: 0.0 · 95% CI -0.3 to 0.4
SecondaryPercentage of Subjects With Treatment Response at Week 12 (Defined as Improvement From Baseline ≥8 Points) Based on the HQ-CT Score at Week 12

Treatment response was defined as an improvement from Baseline of at least 8 points in the HQ-CT total score at Week 12. The HQ-CT is a caregiver-reported, 9-item assessment of observable hyperphagia-related behaviors in participants with PWS. Total scores range from 0 to 36, with higher scores indicating greater severity of hyperphagia. Participants meeting the ≥8-point improvement threshold were classified as responders.

Time frame:
Week 12
Reported as:
Count of participants · Participants
Percentage of Subjects With Treatment Response at Week 12 (Defined as Improvement From Baseline ≥8 Points) Based on the HQ-CT Score at Week 12
ParticipantsCarbetocinPlacebo
Percentage of Subjects With Treatment Response at Week 12 (Defined as Improvement From Baseline ≥8 Points) Based on the HQ-CT Score at Week 122532
Statistical analysis
  • Carbetocin vs Placebo · Regression, Logistic · p = 0.4992 · Odds ratio (or): 0.8 · 95% CI 0.4 to 1.5
SecondaryChange From Baseline at Week 12 in CGI-S for Hyperphagia in PWS Score

The CGI-S for PWS is a clinician-rated assessment of the overall severity of PWS symptoms at the time of evaluation. The CGI-S is rated on a 7-point scale ranging from 1 (normal, not at all ill) to 7 (among the most severely ill participants), with higher scores indicating greater illness severity. The assessment is performed by the Investigator or a trained, qualified designee, and the same rater is expected to evaluate a given participant throughout the study whenever possible to maintain rating consistency.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · Score on a scale
Change From Baseline at Week 12 in CGI-S for Hyperphagia in PWS Score
Score on a scaleCarbetocinPlacebo
Change From Baseline at Week 12 in CGI-S for Hyperphagia in PWS Score-0.7 ± 0.12-0.7 ± 0.12
Statistical analysis
  • Carbetocin vs Placebo · Mixed-effects model for repeated measure · p = 0.6400 · Lsm difference: -0.1 · 95% CI -0.4 to 0.3

Adverse events

Collected over From first dose of study drug through 30 days after the last dose (end of safety follow-up), up to approximately 16 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Carbetocin0/83 (0%)0/83 (0%)11/83 (13.3%)
Placebo0/88 (0%)0/88 (0%)9/88 (10.2%)
Most frequent other events
Most frequent other events
EventCarbetocinPlacebo
HeadacheNervous system disorders6/833/88
PyrexiaGeneral disorders5/831/88
DiarrheaGastrointestinal disorders2/835/88

Baseline characteristics

Baseline characteristics are reported for enrolled participants with PWS only. Caregivers participated as informants for caregiver-reported study assessments and were not enrolled study participants, were not randomized, and are not included in baseline characteristic summaries.

Age, Customized
Age, Customized(Participants)CarbetocinPlaceboTotal
<12 years404181
≥12 to <17 years202343
≥17 years252651
Sex: Female, Male
Sex: Female, Male(Participants)CarbetocinPlaceboTotal
Female4659105
Male393170
Race (NIH/OMB)
Race (NIH/OMB)(Participants)CarbetocinPlaceboTotal
American Indian or Alaska Native101
Asian325
Native Hawaiian or Other Pacific Islander000
Black or African American123
White7181152
More than one race628
Unknown or Not Reported336
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)CarbetocinPlaceboTotal
Hispanic or Latino11617
Not Hispanic or Latino7077147
Unknown or Not Reported4711
Prior Carbetocin Use
Prior Carbetocin Use(Participants)CarbetocinPlaceboTotal
Yes131528
No7275147
08

Study locations

30 sites
  • Children's of Alabama
    Birmingham, Alabama 35233, United States
  • Phoenix Children's Hospital
    Phoenix, Arizona 85006, United States
  • University of California Irvine
    Orange, California 92697, United States
  • Stanford University School of Medicine
    Palo Alto, California 94304, United States
  • Rady Children's Hospital San Diego
    San Diego, California 92123, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
  • SSM Health/Saint Louis University
    St Louis, Missouri 63104, United States
  • Maimonides Medical Center
    Brooklyn, New York 11219, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • UPMC-Children's Hospital Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • Vanderbilt Clinical Research Center
    Nashville, Tennessee 37232, United States
  • Cook Children's Health Care System
    Fort Worth, Texas 79104, United States
  • Christus Children's
    San Antonio, Texas 78207, United States
  • University of Utah
    Salt Lake City, Utah 84108, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • Alberta Diabetes Institute
    Edmonton, Alberta T6G 2E1, Canada
  • CHU Sainte Justine
    Montreal, Quebec H3T 1C5, Canada
  • Centre Hospitalier Universitaire (CHU) de Toulouse - Hôpital des Enfants
    Toulouse, 31059, France
  • KJF Klinik Josefinum gGmbH
    Augsburg, 86154, Germany
  • Universitätsklinikum Essen
    Essen, 45147, Germany
  • Parc Taulí Hospital Universitari
    Barcelona, 08208, Spain
  • Hospital General Universitario Gregorio Marañón
    Madrid, 28009, Spain
  • Hospital Regional Universitario de Málaga
    Málaga, 29010, Spain
  • University Hospitals Birmingham NHS Foundation Trust - Heartlands Hospital
    Birmingham, B9 5SS, United Kingdom
  • Royal Hospital for Children Glasgow Clinical Research Facility
    Glasgow, G51 4TF, United Kingdom
  • Barts Health NHS Trust - The Royal London Hospital
    London, E1 1BB, United Kingdom
09

References and documents

Publications

  • Roof E, Strong TV, Stafford DEJ, Singh D, Roy SM, Doshi D, Zhang Y, Salvucci A, Youakim JM, McCandless SE; COMPASS PWS Investigators. Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome: Results From the Randomized, Placebo-Controlled, Phase 3 Compass PWS Study. Clin Ther. 2026 Jul 22:S0149-2918(26)00234-1. doi: 10.1016/j.clinthera.2026.06.019. Online ahead of print. PubMed 42486751 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Nov 2023 to primary completion in Aug 2025, 20 months.

Results were first posted in Oct 2026, 1 year 1 month after primary completion.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Oct 2025 → Aug 2025 and completion Nov 2025 → Aug 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2023
First posted
Dec 15, 2023
StartActual
Nov 27, 2023
Primary completionActual
Aug 19, 2025was Oct 2025
CompletionActual
Aug 19, 2025was Nov 2025
Results first posted
Oct 15, 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 15, 2026
Results
Results posted
posted Oct 15, 2026
Primary completion
Oct 2025→Aug 19, 2025 (actual)
Oct 15, 2026
Study completion
Nov 2025→Aug 19, 2025 (actual)
Oct 15, 2026
Enrollment
170 (estimated)→175 (actual)
Oct 15, 2026
Eligibility
3 inclusion criteria edited, 2 added, 3 removed; 5 exclusion criteria edited, 5 added, 8 removed
What changed in the criteria
Inclusion criteria
  • EditedMale or female andparticipants aged 5 throughto 30 years of age
  • EditedDiagnosis of Prader-Willi syndrome with a documented disease-causing genetic mutation
  • RemovedIncreased appetite with decreased satiety accompanied by food seeking (consistent with PWS Nutritional Phase 3)
  • RemovedHQ-CT total score of ≥13 at Screening and Baseline
  • RemovedCGI-S score for hyperphagia in PWS of ≥4 at Screening and Baseline
  • AddedEvidence of hyperphagia, including increased appetite and decreased satiety with food-seeking behaviors
  • AddedMeeting minimum severity thresholds for hyperphagia based on validated clinical assessments at Screening and Baseline
  • EditedLivesResiding with a caregiver who understandsis able and is willing and able to adhere tocomply with study-related procedures and is willing to participate in all study visits
Exclusion criteria
  • EditedGenetically diagnosed withDiagnosis of Schaaf-Yang syndrome or another genetic, hormonal, or chromosomal cognitive impairment besides PWSdisorder other than Prader-Willi syndrome
  • EditedAn activeActive upper respiratory infection at the Screening visit or the Baseline visit
  • EditedAny clinicallyClinically significant medical conditions that could interfere with study participation or interpretation of results (e.g., cardiovascular disorder, renal, hepatic, gastrointestinal, or respiratory disease, including severe asthma)
  • EditedHistory of, or current significant neurological conditions (e.g., cerebrovascular disease, brain trauma, epilepsy, or frequent migraines. A), except for a history of febrile seizures is not exclusionary
  • RemovedNasal surgery within 1 month of Screening visit or planning to have nasal surgery during the study.
  • RemovedUnwilling to abstain from nasal saline, other nasal irrigation, and other intranasal medications during the Screening period and through the treatment period of the study
  • RemovedClinically significant irritability or agitation, requiring initiation of or increase in the dose of antipsychotic medication, within the 6 months prior to the Screening visit
  • RemovedUsed prostaglandins, prostaglandin analogues, or prostaglandin agonists in the 3 months prior to the Baseline visit. Inhibitors of prostaglandin synthesis, such as nonsteroidal anti-inflammatory drugs, are not exclusionary.
  • RemovedStarted a glucagon-like peptide 1 (GLP-1) agonist within the 6 months prior to the Screening visit. Treatment with GLP-1 agonist is allowed if the subject has been taking it for more than 6 months prior to Screening.
  • RemovedUsed oxytocin, desmopressin (DDAVP), tesofensine, diazoxide choline, melanocortin-4 receptor (MC4R) agonists (e.g., setmelanotide), or any medication approved to treat hyperphagia within 6 months prior to the Baseline visit
  • RemovedActive psychotic symptoms, a history of psychotic symptoms, or a psychotic disorder
  • AddedRecent or planned nasal surgery that could affect intranasal drug administration
  • AddedUnwillingness to restrict use of intranasal medications that may interfere with study treatment
  • AddedRecent clinically significant psychiatric instability, including irritability or agitation requiring changes in antipsychotic therapy
  • AddedUse of medications or treatments that may interfere with the evaluation of hyperphagia or study endpoints within a defined period prior to Screening Active psychotic disorder or history of significant psychotic symptoms
  • RemovedNew food-related interventions, including environment or dietary restrictions, within 1 month prior to the Screening visit or during the Screening period (i.e., before the Baseline visit)
  • AddedRecent changes in food-related behavioral or environmental interventions that may confound assessment of hyperphagia
  • EditedAdditional inclusion/ and exclusion criteria apply. SubjectsParticipants will be evaluated at screeningScreening to ensure that all criteria for study participationeligibility requirements are met.
Oct 15, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange fromFrom Baseline at Week 12 in caregiver-rated Hyperphagia Questionnaire for Clinical Trials (HQ-CT) scoreScoreTime frame: Baseline to Week 12
Oct 15, 2026
Documents
Secondary outcomes
2 edited, 2 added
What changed in the outcomes
  • EditedChange fromFrom Baseline at Week 12 in caregiver-rated Clinical Global Impression- of Severity (CGI-S) score for PWS ScoreTime frame: Baseline to Week 12
  • EditedClinical Global Impression- of Change (CGI-C) for PWS scoreScore at Week 12Time frame: Score at Week 12 → Week 12
  • AddedPercentage of Subjects With Treatment Response at Week 12 (Defined as Improvement From Baseline ≥8 Points) Based on the HQ-CT Score at Week 12Time frame: Week 12
  • AddedChange From Baseline at Week 12 in CGI-S for Hyperphagia in PWS ScoreTime frame: Baseline to Week 12
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Active, not recruiting→Completed
    Results posted
    Primary completion Oct 2025→Aug 19, 2025 (now actual)
    Study completion Nov 2025→Aug 19, 2025 (now actual)
    Enrollment 170 (estimated)→175 (actual)
    Eligibility 3 inclusion criteria edited, 2 added, 3 removed; 5 exclusion criteria edited, 5 added, 8 removed
    What changed in the criteria
    Inclusion criteria
    • EditedMale or female andparticipants aged 5 throughto 30 years of age
    • EditedDiagnosis of Prader-Willi syndrome with a documented disease-causing genetic mutation
    • RemovedIncreased appetite with decreased satiety accompanied by food seeking (consistent with PWS Nutritional Phase 3)
    • RemovedHQ-CT total score of ≥13 at Screening and Baseline
    • RemovedCGI-S score for hyperphagia in PWS of ≥4 at Screening and Baseline
    • AddedEvidence of hyperphagia, including increased appetite and decreased satiety with food-seeking behaviors
    • AddedMeeting minimum severity thresholds for hyperphagia based on validated clinical assessments at Screening and Baseline
    • EditedLivesResiding with a caregiver who understandsis able and is willing and able to adhere tocomply with study-related procedures and is willing to participate in all study visits
    Exclusion criteria
    • EditedGenetically diagnosed withDiagnosis of Schaaf-Yang syndrome or another genetic, hormonal, or chromosomal cognitive impairment besides PWSdisorder other than Prader-Willi syndrome
    • EditedAn activeActive upper respiratory infection at the Screening visit or the Baseline visit
    • EditedAny clinicallyClinically significant medical conditions that could interfere with study participation or interpretation of results (e.g., cardiovascular disorder, renal, hepatic, gastrointestinal, or respiratory disease, including severe asthma)
    • EditedHistory of, or current significant neurological conditions (e.g., cerebrovascular disease, brain trauma, epilepsy, or frequent migraines. A), except for a history of febrile seizures is not exclusionary
    • RemovedNasal surgery within 1 month of Screening visit or planning to have nasal surgery during the study.
    • RemovedUnwilling to abstain from nasal saline, other nasal irrigation, and other intranasal medications during the Screening period and through the treatment period of the study
    • RemovedClinically significant irritability or agitation, requiring initiation of or increase in the dose of antipsychotic medication, within the 6 months prior to the Screening visit
    • RemovedUsed prostaglandins, prostaglandin analogues, or prostaglandin agonists in the 3 months prior to the Baseline visit. Inhibitors of prostaglandin synthesis, such as nonsteroidal anti-inflammatory drugs, are not exclusionary.
    • RemovedStarted a glucagon-like peptide 1 (GLP-1) agonist within the 6 months prior to the Screening visit. Treatment with GLP-1 agonist is allowed if the subject has been taking it for more than 6 months prior to Screening.
    • RemovedUsed oxytocin, desmopressin (DDAVP), tesofensine, diazoxide choline, melanocortin-4 receptor (MC4R) agonists (e.g., setmelanotide), or any medication approved to treat hyperphagia within 6 months prior to the Baseline visit
    • RemovedActive psychotic symptoms, a history of psychotic symptoms, or a psychotic disorder
    • AddedRecent or planned nasal surgery that could affect intranasal drug administration
    • AddedUnwillingness to restrict use of intranasal medications that may interfere with study treatment
    • AddedRecent clinically significant psychiatric instability, including irritability or agitation requiring changes in antipsychotic therapy
    • AddedUse of medications or treatments that may interfere with the evaluation of hyperphagia or study endpoints within a defined period prior to Screening Active psychotic disorder or history of significant psychotic symptoms
    • RemovedNew food-related interventions, including environment or dietary restrictions, within 1 month prior to the Screening visit or during the Screening period (i.e., before the Baseline visit)
    • AddedRecent changes in food-related behavioral or environmental interventions that may confound assessment of hyperphagia
    • EditedAdditional inclusion/ and exclusion criteria apply. SubjectsParticipants will be evaluated at screeningScreening to ensure that all criteria for study participationeligibility requirements are met.
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange fromFrom Baseline at Week 12 in caregiver-rated Hyperphagia Questionnaire for Clinical Trials (HQ-CT) scoreScoreTime frame: Baseline to Week 12
    Secondary outcomes 2 edited, 2 added
    What changed in the outcomes
    • EditedChange fromFrom Baseline at Week 12 in caregiver-rated Clinical Global Impression- of Severity (CGI-S) score for PWS ScoreTime frame: Baseline to Week 12
    • EditedClinical Global Impression- of Change (CGI-C) for PWS scoreScore at Week 12Time frame: Score at Week 12 → Week 12
    • AddedPercentage of Subjects With Treatment Response at Week 12 (Defined as Improvement From Baseline ≥8 Points) Based on the HQ-CT Score at Week 12Time frame: Week 12
    • AddedChange From Baseline at Week 12 in CGI-S for Hyperphagia in PWS ScoreTime frame: Baseline to Week 12
    + 4 other changes: identifiers, verification date, arm descriptions and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06173531
Responsible party
Sponsor
First posted
Dec 15, 2023
Start date
Nov 27, 2023
Primary completion
Aug 19, 2025
Completion
Aug 19, 2025
Results posted
Oct 15, 2026
Last update
Oct 15, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Carbetocin

Start the discussion